Replies to post #2219 on PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[n3m3sis]

Sadly, I do not think so. PSTI (Pluristem on the NASDaq) suffers the same way. It's as if they have to report 50 times better than other biotechs to really move.
In PSTI's case they have over 100 patents protecting their IP and have turned down buyout offers out of hand. Its really sad